Wayne Koberstein

Jul 16, 2024 | lifescienceleader.com | Wayne Koberstein

By Wayne Koberstein, Executive Editor, Life Science Leader Follow Me On Twitter @WayneKoberstein To protect and restore neuronal networks by enhancing natural repair processes. Snapshot Athira Pharma takes a small-molecule approach to targeting the neurotrophic hepatocyte growth factor (HGF) system for neurodegenerative diseases.

Mar 29, 2024 | lifescienceleader.com | Wayne Koberstein

By Wayne Koberstein, Executive Editor, Life Science Leader Follow Me On Twitter @WayneKoberstein Resalis Enters the Widening Space of Weight Loss Discovery and accident are two words married at the hip. If you’re in the business of discovery, you should prepare for the fortunate accident, the kind that shows a pathway to something new and beneficial, one that takes you away from your original goal entirely and guides you thereafter toward a brand new destination.

Mar 1, 2024 | lifescienceleader.com | Wayne Koberstein

By Wayne Koberstein, Executive Editor, Life Science Leader magazineFollow Me On Twitter @WayneKoberstein Inozyme’s Leader Shares Informed Views In the decades since the United States passed the Orphan Drug Act in 1983, its policies have succeeded in raising the number of drugs developed for rare diseases. Incentives in the Act were so effective, in fact, orphan drugs may have replaced blockbusters as the driving force of biopharma.

Feb 27, 2024 | lifescienceleader.com | Wayne Koberstein

By Wayne Koberstein, Executive Editor, Life Science Leader magazineFollow Me On Twitter @WayneKoberstein Targeting the continuing need for HPV treatment with a topical antiviral. SNAPSHOT Antiva Biosciences is developing a new drug, coded ABI-2280, for treating Human Papilloma Virus (HPV)-related diseases, including precancerous conditions. ABI-2280 is a prodrug of an acyclic nucleoside phosphonate, formulated to improve safety as well as enhance deliverability as a topical medicine.

Feb 1, 2024 | lifescienceleader.com | Wayne Koberstein

By Wayne Koberstein, Executive Editor, Life Science Leader magazineFollow Me On Twitter @WayneKoberstein Developing a potential small molecule breakthrough to challenge the biopharma paradigm. SNAPSHOT Promontory Therapeutics aims not only for the kind of innovation that improves the action of a drug class, but also for a revolution in how a drug accomplishes that action.